Australia's Orthocell surges on sales approval in Singapore

Orthocell

18/03/2025 24:14

** Shares of Orthocell OCC.AX rise 11% to A$1.52, hitting their highest levels since Feb 20

** The biotech firm receives regulatory approval from Singapore's Health Sciences authority to start sales of its Striate+ product

** Striate+ is a dental guided bone regeneration product

** Says co working with Striate+ distribution partner BioHorizons to fast-track expansion to other regions including Brazil

** Stock up ~11.1% YTD, including current session's moves

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))